Table 1 Demographic and clinical characteristics of training sets and validation sets
predictors | Training cohort(n = 258) | P | Validation cohort(n = 110) | P | ||
|---|---|---|---|---|---|---|
Musculoskeletal pain(n = 118) | Non-musculoskeletal pain (n = 140 ) | Musculoskeletal pain(n = 46) | Non-musculoskeletal pain (n = 64) | |||
Gender,n(%) | 0.256 | 0.701 | ||||
Male | 20(17.8%) | 33 (23.6%) | 8 (17.4%) | 13 (20.3%) | ||
Female | 98(82.2%) | 107(76.4%) | 38 (82.6%) | 51 (79.7%) | ||
Age,years,n(%) | 0.000 | 0.000 | ||||
< 60 60–70 70–80 | 5 (4.3%) 22 (18.6%) 68 (57.6%) | 7 (5.0%) 16 (11.4%) 20 (14.3%) | 3 (6.5%) 19 (41.3%) 13 (28.3%) | 3 (4.7%) 5(7.8%) 14 (21.9%) | ||
>80 | 23 (19.5%) | 97 (69.3%) | 11 (23.9%) | 42 (65.6%) | ||
BMI, n(%) | 0.000 | 0.001 | ||||
< 24 | 77 (65.3%) | 57 (40.7%) | 30 (65.2%) | 22 (34.4%) | ||
≥ 24 | 41 (32.7%) | 83 (59.3%) | 16 (34.8%) | 42 (65.6%) | ||
NSAIDs | 0.003 | 0.000 | ||||
Yes | 15(12.7%) | 115(82.1%) | 7(15.2%) | 51(79.7%) | ||
No | 103(87.3%) | 25(17.9%) | 39(84.8%) | 13(20.3%) | ||
Fluidinfusion | 0.000 | 0.027 | ||||
Yes | 68 (57.6%) | 92 (65.7%) | 33(55.4%) | 34(52.9%) | ||
No | 50 (42.4%) | 50 (42.4%) | 13(44.6%) | 30(47.1%) | ||
Fracture | 0.668 | 0.977 | ||||
Yes | 55(46.6%) | 69(49.3%) | 20(43.5%) | 28(43.8%) | ||
No | 63(53.4%) | 71(50.7%) | 26(56.5%) | 36(56.3%) | ||
25(OH)D | 0.000 | 0.000 | ||||
< 30 | 90(76.3%) | 38(27.1%) | 32(69.6%) | 18(28.1%) | ||
≥ 30 | 28(23.7%) | 102(72.9%) | 14(30.4%) | 46(71.9%) | ||
PTH | 0.050 | 0.562 | ||||
< 70 | 93(73.8%) | 123(87.9%) | 36(78.3%) | 47(73.4%) | ||
≥ 70 | 25(21.2%) | 17(12.1%) | 10 (21.7%) | 17(26.6%) | ||
OC | 0.196 | 0.033 | ||||
15–46 | 93(78.8%) | 119(85.0%) | 29(63.0%) | 52(81.2%) | ||
≤ 15 or ≥ 46 | 25(21.2%) | 21(15.0%) | 17(37.0%) | 12(18.8%) | ||
T-index | 0.777 | 0.899 | ||||
≤-2.5 | 72(60.0%) | 83(59.3%) | 25(54.3%) | 34(53.1%) | ||
0-2.5–3.0 | 46(39.0%) | 57(40.7%) | 21(46.7%) | 30(46.9%) | ||
prior Vitamin D intake | 0.000 | 0.000 | ||||
supplement | 96(81.4%) | 30(21.4%) | 37(80.4%) | 21(32.8%) | ||
no supplement | 22(18.6%) | 111(78.6%) | 9(19.6%) | 43(67.2%) | ||